


See "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies" on page 475-486.



**Supplementary Fig. 1.** Change in CRP concentration through week 8 of induction studies. Panel B and D are adapted from Feagan BG, et al. *N Engl J Med* 2016;375:1946-1960, with permission Massachusetts Medical Society.<sup>19</sup>